NEW YORK, November 16, 2018 /PRNewswire/ --
According to data compiled by Mordor Intelligence, the Hospital AcquiredInfection Control Market is expected to reach USD 33.78 Billion by 2021 and is growing at a CAGR of 8.3% during the forecasted. The market being driven by the demand to control spread of infections within a hospital environment,
Infections caused on site at facilities has become a growing concern, which is why the market is developing and expanding upon medical equipment. The use of sterilized and disinfected medical equipment can help further prevent infections from spreading. New technology advancements are helping with detection, tracking, isolation and treatment. "As infection prevention challenges evolve-such as emerging infectious organisms and resistance-healthcare organizations must focus on preventing hospital-acquired infections and ensuring better patient outcomes." said Lena Browning MHA, BSN, RN at Compass Clinical Consulting, "To achieve these goals, Infection Prevention professionals must be involved in all decisions affecting the delivery of patient care. Healthcare is ever-changing, and innovative approaches are critical as we look to the future of infection prevention."
PCT Ltd. (OTC: PCTL) announced breaking news last week that it, "has reached significant company milestones through its wholly-owned operating subsidiary Paradigm Convergence Technologies Corporation (PCT Corp.). PCT Corp. has successfully completed two Beta Site trials and installations at major healthcare facilities, which have been converted into long-term agreements for its Annihilyzer® Infection Control Systems. PCT Corp. has also established agreements with several Manufacturing Representatives for geographical territories in the healthcare market. With these milestones achieved, PCT Corp. has commenced the full-scale marketing launch of its hospital infection control systems.
PCT LTD announced today that Jody Read, current Chief Operating Officer, was promoted to Chief Executive Officer of PCT LTD and PCT Corp. Mr. Read will continue his duties as COO until it is determined that the position needs to be filled by additional personnel. Gary Grieco, PCT LTD's current CEO, will continue as Chairman of the Board of PCT LTD and will focus his attention on setting the course for the company and overseeing the Board.
Since 2014, Gary Grieco in his prior role as PCT LTD's CEO, has successfully built and secured funding for PCT Corp., as a startup company. He acquired and developed under his leadership its patented, proprietary technologies and directed the development of PCT Corp.'s products to the point in which PCT Corp. now has proof of concept and commercial entry in its target markets.
Read joined PCT Corp. two years ago after successfully founding and managing Customer Service Associates, Inc. (CSA) for 18 years, a $44 Million dollar a year sales and support organization for the healthcare market with over 350 employees providing equipment and services for the largest OEM's in healthcare. He has over 33 years of medical industry background working for and with the largest manufacturers in the medical equipment business. Read's skills in management, organization, sales, service and support will provide PCT with the leadership required to move PCT Corp. into the defined markets PCT has initially targeted.
Gary Grieco stated, "Jody has proven himself over the past two years to be a great team leader and his expertise in business management and healthcare equipment technologies will take PCTL and PCT Corp. to the next levels of growth and profitability. I look forward to working with Jody and the entire PCT Team to drive PCT's growth."
About PCT LTD - PCT LTD ("PCTL") focuses its business on acquiring, developing and providing sustainable, environmentally safe disinfecting and tracking technologies products. The company acquires and holds rights to innovative products and technologies, which are commercialized through its wholly-owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp). Currently trading on OTC, "PCTL" aspires to and is actively engaged in preparations for up-listing its common stock to a national securities exchange. The Company established entry into its target markets with commercially-viable products and now prepares to gain market share. PCT Corp's business mission is to profitably provide state-of-the-art Electro-Chemical Activation equipment, disinfecting fluid solutions and PCT Corp's patented tracking system to hospitals and other facilities for the documentable remediation of Hospital Acquired Infections (HAI's) from organisms such as Clostridium difficile (C. diff.), MRSA, VRE, CRE, Klebsiella pneumoniae, and Pseudomonas, as well as to sell ECA fluid solutions to agricultural markets for the remediation, control and suppression of microbial contamination and disease of certain commercial crops. The Company's primary fluid solution, branded Hydrolyte®, is an EPA registered "hospital-level" disinfectant effective against common healthcare pathogens such as Tuberculosis (TB), HIV-1, Hepatitis C, Norovirus, Rhinovirus, Influenza A, Candida albicans, and more; food processing bacteria including E. coli, Listeria, and Salmonella; and organisms of veterinarian concern such as parvovirus, distemper and Bordetella. PCT Corp.'s proprietary equipment product line includes: 1) PCT Hydrolyte® Generators, 2) PCT Annihilyzer® Infection Control Systems, and 3) SurvivaLyte® equipment. The Hydrolyte® Generators produce large volumes of electrolyzed water for the agriculture, oil and gas, and fluid distribution markets. The Annihilyzer® Infection Control Systems, which boast patented RFID material tracking technology, Electrostatic Smart Applicators, on-site automated ECA generators, and Green Seal standards containing stringent performance, health, and sustainability criteria, are ideal for hospitals and healthcare facilities. The SurvivaLyte® unit is a portable, small volume generator with applications such as disaster recovery, emergency preparedness, remote on-site needs, farm and ranch, and personal use. PCT Corp's unique patented systems and human-safe products provide next-generation cleaning, sanitizing, disinfecting and decontaminating fluid solutions to the ever-present problems of microbial infection and infestation."
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel Pharmaceuticals, Inc. recently announced that it had entered into an exclusive license and supply agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") to develop and commercialize TAVALISSE™ in all current and potential indications in Japan, China, Taiwan and the Republic of Korea. Kissei is a Japan-based pharmaceutical company addressing patients' unmet medical needs through its research, development and commercialization efforts, as well as through collaborations with partners. TAVALISSE is commercially available in the U.S. for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. "Kissei is a leading Japanese pharmaceutical company with significant development experience and a track record of commercial success in Asian markets. Their commitment to develop TAVALISSE in ITP, and potential future indications in these territories, makes Kissei an optimal partner as we seek to expand the global market opportunity for this important new therapeutic," said Raul Rodriguez, President and Chief Executive Officer of Rigel. "This agreement demonstrates our approach to entering strategic markets outside of the U.S. and emphasizes the unmet need that exists for chronic ITP, among other rare blood disorders."
Achaogen, Inc. (NASDAQ: AKAO) is a biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen, Inc. recently announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for plazomicin. The Company is seeking approval for the following indications: Complicated urinary tract infections (cUTI), including pyelonephritis Bloodstream infections (BSI) due to certain Enterobacteriaceae and; Infections due to Enterobacteriaceae in adult patients with limited treatment options. "Our mission is to bring much-needed antibiotics to patients globally and, with this MAA submission, we are one step closer to that goal," said Blake Wise, Achaogen's Chief Executive Officer. "We look forward to the acceptance of this application and the potential to bring a new treatment option to EU patients and healthcare professionals who face the daily challenge of treating recurrent and resistant gram-negative infections."
Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and the Centers for Disease Control and Prevention. Tetraphase Pharmaceuticals, Inc. recently announced data from two post-hoc analyses of pooled data from two Phase 3 IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) studies of XERAVA in patients with complicated intra-abdominal infections (cIAI). "Treatment failure risk can increase in certain subgroups with cIAI, including patients who are obese, and those with altered renal function," said Larry Tsai, M.D., Chief Medical Officer of Tetraphase. "Obesity may put patients at higher risk due to altered pharmacokinetics and comorbidities, while renal function can be highly dynamic in patients with serious infections, which can result in significant over- or under-dosing of antibiotics."
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS, Inc. recently announced that the U.S. Food and Drug Administration (FDA) has granted both Qualified Infectious Disease Product (QIDP) and Fast Track designations for the oral formulation of SCY-078, SCYNEXIS's novel oral and intravenous antifungal agent, for the treatment of vulvovaginal candidiasis (VVC) and for the prevention of recurrent VVC. Additionally, SCYNEXIS today announced it has completed enrollment in the Phase 2b, dose-finding study of oral SCY-078 for the treatment of VVC (the DOVE study), with release of top-line data expected by July 2018. "These designations from the FDA for the treatment of VVC and prevention of recurrent VVC highlight the significant unmet needs faced by women suffering from these widespread infections," said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. "We believe SCY-078 will provide a beneficial treatment option for healthcare providers and women not satisfied with existing therapies. Moreover, we can now make use of the QIDP and Fast Track designations across all current SCY-078 development programs, including VVC, invasive candidiasis and invasive aspergillosis."
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
For further information: Media Contact: firstname.lastname@example.org +1-877-601-1879
Subscribe to our Free Newsletters!